脑影像上的梗死灶、后续缺血性卒中与氯吡格雷-阿司匹林疗效:一项随机临床试验的事后分析
该研究为POINT随机临床试验的事后分析,纳入4876例高风险短暂性脑缺血发作或轻型缺血性卒中患者,按指数影像有无急性梗死灶分组。指数影像有急性梗死灶与随访期间缺血性卒中风险升高相关(HR 3.68),且氯吡格雷-阿司匹林相比单用阿司匹林在有梗死灶患者中与缺血性卒中风险降低相关(HR 0.56),交互作用显著(P=0.008)。
要点
- 指数影像有急性梗死灶者随访缺血性卒中风险升高(HR 3.68;95%CI 2.73-4.95;P<.001)。
- 有梗死灶患者中氯吡格雷-阿司匹林较单用阿司匹林与缺血性卒中风险降低相关(HR 0.56)。
- 无梗死灶患者中氯吡格雷-阿司匹林与单用阿司匹林相比无显著差异(HR 1.11;95%CI 0.74-1.65;P=.62)。
核心结论
- 指数影像存在急性梗死灶与复发性卒中风险升高相关,且与氯吡格雷-阿司匹林更明显的获益相关。
- 作者认为未来工作应聚焦于验证这些发现,之后再针对特定患者群体进行急性氯吡格雷-阿司匹林治疗。
研究设计与样本
- POINT随机临床试验的事后分析,纳入2010年5月28日至2017年12月19日在北美、欧洲、澳大利亚和新西兰10个国家269个中心入组的高风险短暂性脑缺血发作和轻型缺血性卒中患者。
- 4881例入组患者中4876例(99.9%)符合纳入标准,平均(标准差)年龄65(13)岁,男性2685例(55.0%)。
- 按指数影像有无急性梗死灶分为2组,采用单变量Cox回归模型评估关联及效应修饰。
- 数据分析时间为2020年7月至2021年5月。
主要发现
- 1793例患者(36.8%)指数影像有急性梗死灶。
- 指数影像有梗死灶与随访期间缺血性卒中相关(HR 3.68;95%CI 2.73-4.95;P<.001)。
- 有梗死灶患者中氯吡格雷-阿司匹林相比单用阿司匹林与缺血性卒中风险降低相关(HR 0.56;95%CI 0.41-0.77;P<.001)。
- 无梗死灶患者中氯吡格雷-阿司匹林相比单用阿司匹林与缺血性卒中风险无显著差异(HR 1.11;95%CI 0.74-1.65;P=.62)。
- 交互作用显著(P for interaction=.008)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: In the Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) trial, acute treatment with clopidogrel-aspirin was associated with significantly reduced risk of recurrent stroke. There may be specific patient groups who are more likely to benefit from this treatment. OBJECTIVE: To investigate whether the association of clopidogrel-aspirin with stroke recurrence in patients with minor stroke or high-risk transient ischemic attack (TIA) is modified by the presence of infarct on imaging attributed to the index event (index imaging) among patients enrolled in the POINT Trial. DESIGN, SETTING, AND PARTICIPANTS: In the POINT randomized clinical trial, patients with high-risk TIA and minor ischemic stroke were enrolled at 269 sites in 10 countries in North America, Europe, Australia, and New Zealand from May 28, 2010, to December 19, 2017. In this post hoc analysis, patients were divided into 2 groups according to whether they had an acute infarct on index imaging. All POINT trial participants with information available on the presence or absence of acute infarct on index imaging were eligible for this study. Univariable Cox regression models evaluated associations between the presence of an infarct on index imaging and subsequent ischemic stroke and evaluated whether the presence of infarct on index imaging modified the association of clopidogrel-aspirin with subsequent ischemic stroke risk. Data were analyzed from July 2020 to May 2021. EXPOSURES: Presence or absence of acute infarct on index imaging. MAIN OUTCOMES AND MEASURES: The primary outcome is whether the presence of infarct on index imaging modified the association of clopidogrel-aspirin with subsequent ischemic stroke risk. RESULTS: Of the 4881 patients enrolled in POINT, 4876 (99.9%) met the inclusion criteria (mean [SD] age, 65 [13] years; 2685 men [55.0%]). A total of 1793 patients (36.8%) had an acute infarct on index imaging. Infarct on index imaging was associated with ischemic stroke during follow-up (hazard ratio [HR], 3.68; 95% CI, 2.73-4.95; P < .001). Clopidogrel-aspirin vs aspirin alone was associated with decreased ischemic stroke risk in patients with an infarct on index imaging (HR, 0.56; 95% CI, 0.41-0.77; P < .001) compared with those without an infarct on index imaging (HR, 1.11; 95% CI, 0.74-1.65; P = .62), with a significant interaction association (P for interaction = .008). CONCLUSIONS AND RELEVANCE: In this study, the presence of an acute infarct on index imaging was associated with increased risk of recurrent stroke and a more pronounced benefit from clopidogrel-aspirin. Future work should focus on validating these findings before targeting specific patient populations for acute clopidogrel-aspirin treatment.
引用
- Rostanski SK, Kvernland A, Liberman AL, et al. Infarct on Brain Imaging, Subsequent Ischemic Stroke, and Clopidogrel-Aspirin Efficacy: A Post Hoc Analysis of a Randomized Clinical Trial. JAMA Neurol. 2022. PMID: 35040913. doi:10.1001/jamaneurol.2021.4905
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。